<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id>
    <journal-id journal-id-type="publisher-id">pr</journal-id>
    <journal-id journal-id-type="coden">jprobs</journal-id>
    <journal-title-group>
      <journal-title>Journal of Proteome Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-3893</issn>
    <issn pub-type="epub">1535-3907</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8256816</article-id>
    <article-id pub-id-type="pmid">34165986</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jproteome.1c00190</article-id>
    <article-categories>
      <subj-group>
        <subject>Technical Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>BlackSheep: A Bioconductor and Bioconda Package for Differential Extreme Value
Analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Blumenberg</surname>
          <given-names>Lili</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
        <xref rid="notes3" ref-type="notes">⊥</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Kawaler</surname>
          <given-names>Emily A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff3" ref-type="aff">§</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
        <xref rid="notes3" ref-type="notes">⊥</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <name>
          <surname>Cornwell</surname>
          <given-names>MacIntosh</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
        <xref rid="notes3" ref-type="notes">⊥</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <name>
          <surname>Smith</surname>
          <given-names>Shaleigh</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath5">
        <name>
          <surname>Ruggles</surname>
          <given-names>Kelly V.</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath6">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5049-3825</contrib-id>
        <name>
          <surname>Fenyö</surname>
          <given-names>David</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff3" ref-type="aff">§</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Vilcek Institute of Graduate Biomedical Sciences,
<institution>New York University Grossman School of Medicine</institution>, New York,
New York 10016, <country>United States</country></aff>
      <aff id="aff2"><label>‡</label>Division of Translational Medicine, Department of
Medicine, <institution>New York University Grossman School of Medicine</institution>, New
York, New York 10016, <country>United States</country></aff>
      <aff id="aff3"><label>§</label>Department of Biochemistry and Molecular Pharmacology,
<institution>New York University Grossman School of Medicine</institution>, New York,
New York 10016, <country>United States</country></aff>
      <aff id="aff4"><label>∥</label>Institute for Systems Genetics, <institution>New York
University Grossman School of Medicine</institution>, New York, New York 10016,
<country>United States</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Tel: <phone>1-212-263-2216</phone>. Email:
<email>David@FenyoLab.org</email>.</corresp>
      <corresp id="cor2"><label>*</label>Tel: <phone>1-212-263-3642</phone>. Email:
<email>kelly.ruggles@nyulangone.org</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>24</day>
      <month>06</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>02</day>
      <month>07</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>24</day>
      <month>06</month>
      <year>2022</year>
    </pub-date>
    <volume>20</volume>
    <issue>7</issue>
    <fpage>3767</fpage>
    <lpage>3773</lpage>
    <history>
      <date date-type="received">
        <day>09</day>
        <month>03</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Authors. Published by American Chemical
Society</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and
integrity are maintained; but does not permit creation of adaptations or other
derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_0005" id="ab-tgr1"/>
      </p>
      <p>Unbiased assays such as shotgun proteomics and RNA-seq provide high-resolution
molecular characterization of tumors. These assays measure molecules with highly varied
distributions, making interpretation and hypothesis testing challenging. Samples with
the most extreme measurements for a molecule can reveal the most interesting biological
insights yet are often excluded from analysis. Furthermore, rare disease subtypes are,
by definition, underrepresented in cancer cohorts. To provide a strategy for identifying
molecules aberrantly enriched in small sample cohorts, we present BlackSheep, a package
for nonparametric description and differential analysis of genome-wide data, available
from Bioconductor (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bioconductor.org/packages/release/bioc/html/blacksheepr.html">https://www.bioconductor.org/packages/release/bioc/html/blacksheepr.html</uri>) and
Bioconda (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioconda.github.io/recipes/blksheep/README.html">https://bioconda.github.io/recipes/blksheep/README.html</uri>). BlackSheep is a
complementary tool to other differential expression analysis methods, which is
particularly useful when analyzing small subgroups in a larger cohort.</p>
    </abstract>
    <kwd-group>
      <kwd>outliers</kwd>
      <kwd>extreme values</kwd>
      <kwd>differential expression</kwd>
      <kwd>phosphoproteomics</kwd>
      <kwd>proteomics</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Cancer Institute</institution>
            <institution-id institution-id-type="doi">10.13039/100000054</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>U24 CA210972</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>pr1c00190</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>pr1c00190</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Proteogenomic studies characterizing cancer have been completed by many groups, several of
which also conducted phosphoproteome analysis.<sup><xref ref-type="bibr" rid="ref1">1</xref>−<xref ref-type="bibr" rid="ref12">12</xref></sup> Outlier
identification was used in a number of these studies to identify samples with aberrantly
high levels of each phosphosite and phosphoprotein.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> In these studies, outlier identification and subsequent subtype
enrichment were used to interpret phosphopeptide data at the protein level and to highlight
novel putative clinically relevant targets<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref9">9</xref>−<xref ref-type="bibr" rid="ref11">11</xref></sup> or to nominate targets in a kinase inhibitor
screen for sensitizers in drug-resistant cell lines.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> This nonparametric
method is of particular use for multiomics studies, as nonparametric approaches are more
robust to the various sources of technical noise present in these data sets, which violate
assumptions in parametric tests.</p>
    <p>Outlier values in a data set are often assumed to be experimental artifacts and are
typically discarded prior to downstream statistical analyses. However, recurrent outliers
are sometimes the most meaningful values in a data set, representing profound biological
effects. In particular, when characterizing biological systems and identifying disease
vulnerabilities, the largest changes in abundance are often the most
revealing.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup>
Furthermore, many diseases, including cancer, are heterogeneous, with significant molecular
variability requiring highly personalized approaches for successful treatment. The current
strategies for identifying characteristic molecular patterns for groups of samples are
especially underpowered when studying rare disease subtypes, as their sample sizes tend to
be much smaller than those for their more common counterparts. They also tend to rely on
assumptions about the underlying distributions of the features in
question—assumptions that are often inaccurate or discard extreme values with
biological significance. We propose a complementary strategy using the enrichment of outlier
values within subtypes for characterizing disease subtypes that could inform diagnostic
panels and potentially be used in the design of personalized therapeutic strategies for
individual patients.</p>
  </sec>
  <sec id="sec2">
    <title>Materials and Methods</title>
    <p>BlackSheep is an easy-to-use package available on Bioconductor (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bioconductor.org/packages/release/bioc/html/blacksheepr.html">https://www.bioconductor.org/packages/release/bioc/html/blacksheepr.html</uri>) and
Bioconda (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioconda.github.io/recipes/blksheep/README.html">https://bioconda.github.io/recipes/blksheep/README.html</uri>). It can be used in R or
Python or as a command line utility. BlackSheep has two major components: the
“DEVA” (<underline>D</underline>ifferential <underline>E</underline>xtreme
<underline>V</underline>alue <underline>A</underline>nalysis) module for calling outliers,
collapsing features by parent molecule (i.e., phosphopeptides to a protein) and differential
analysis, and the “run_simulations” module for assigning <italic>p</italic>
values to each outlier call. The input data is an expression matrix, structured as rows of
features (genes, proteins, phosphosites, etc.) and columns of samples, and a sample
annotation file is used to group samples for comparisons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_002.xlsx">Supplementary Table 1A,B</ext-link>). No prefiltering is necessary or recommended for
DEVA. Normalization and log<sub>2</sub> transformation of the input matrix is strongly
recommended; a function for sample value normalization is provided.</p>
    <sec id="sec2.1">
      <title>Differential Extreme Value Analysis</title>
      <p>To call outliers, the median and interquartile range (IQR) for each row are calculated.
The user specifies whether to call overly abundant (i.e., up) or depleted (i.e., down)
values. Outliers are defined as any value more than a multiple of the IQR above or below
the median, where the multiple of the IQR is user-specified (default 1.5) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A). Missing values are omitted from this
calculation for each individual feature’s analysis. After calling outliers, there
is an optional aggregation step for collapsing rows containing related features into a
single row (e.g., many phosphosites collapsed into a protein). Aggregation is achieved by
counting outliers and nonoutliers of all phosphosites for each protein. The output is two
tables: one with outlier and nonoutlier counts per protein to be used for downstream
comparisons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_003.xlsx">Supplementary Table 2A,B</ext-link>) and the other containing the fraction of outliers
in each sample, which is helpful for visualization (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_003.xlsx">Supplementary Table 2C,D</ext-link>).</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>BlackSheep workflow. (A) Outliers are initially identified for each feature (row) in
the experimental data set. (B) Simulations and data resampling are used to assign
significance values for each sample and feature. (C) Cohort comparisons identify
features with enriched outliers within a sample cohort of interest.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_0001" id="gr1" position="float"/>
      </fig>
    </sec>
    <sec id="sec2.2">
      <title>Simulations and Outlier <italic>p</italic> Values</title>
      <p>The second main function in the package is “run_simulations”, which uses
simulations based on the observed data to create simulated samples that are used to
calculate a <italic>p</italic> value for each sample for each parent molecule. For each
simulated sample, the procedure is as follows. First, for each feature in the parent
molecule (e.g., phosphosite on a protein), its value in a simulated sample is determined
to be either “observed” or “missing”. The likelihood is based
on the proportion of missing values for that feature in the actual data. This step is most
important in data sets that tend to have an abundance of missing data when imputation is
undesirable. Next, if it is determined to have an “observed” value, then a
random value is assigned from a kernel density estimate (KDE) fit to the observed values
from the associated feature. The assigned value is tested against the outlier threshold
for that feature to determine the outlier status. This is repeated for all features
related to the parent molecule. The frequency of outliers found in the simulated data is
used to assign a <italic>p</italic> value to the observed data based on the number of
outliers found for each parent molecule in each observed sample. A significance threshold
is set at a user-defined alpha (default <italic>p</italic> &lt; 0.05). The output file
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_004.xlsx">Supplementary Table 3</ext-link>) contains a <italic>p</italic> value for outlier
status for each parent molecule in each sample if it reaches significance (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B). This function is useful when the user is
curious about the significance in individual samples rather than in a cohort.</p>
    </sec>
    <sec id="sec2.3">
      <title>Cohort Comparisons</title>
      <p>Groups of samples can be compared with DEVA to identify features with an enrichment of
outliers within a group. BlackSheep calculates the enrichment of outliers, whether
high-expression outliers or low-expression outliers, for every group of samples identified
in a user-supplied sample annotation table (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_002.xlsx">Supplementary Table 1B</ext-link>). The analysis can be limited to a user-supplied list
of genes, such as kinases or known druggable targets.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> To calculate
enrichment, first, a row-based filter is applied, removing rows where the average rate of
outliers for that row is lower in the annotated group of interest (the
“in-group”) than in the out-group. Second, to ensure that results are not
driven by an excessively small subset of the in-group, we only keep rows that have at
least one outlier value in a user-defined proportion of samples in the in-group; the
proportion defaults to 0.3. Finally, DEVA performs Fisher’s exact test on counts
from outlier and nonoutlier values in the in-group against the out-group. All
<italic>p</italic> values are then corrected for multiple hypothesis testing using the
Benjamini–Hochberg procedure.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Results can be output as a table
of <italic>q</italic> values for all comparisons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_003.xlsx">Supplementary Table 2E,F</ext-link>), a table with outlier counts, <italic>p</italic>
values, and <italic>q</italic> values per comparison (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_003.xlsx">Supplementary Table 2G,H</ext-link>), or a heatmap showing outlier fraction values in
each sample for rows with a significant enrichments of outliers (<xref rid="fig1" ref-type="fig">Figures
<xref rid="fig1" ref-type="fig">1</xref></xref>C and <xref rid="fig4" ref-type="fig">4</xref>).</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Results</title>
    <sec id="sec3.1">
      <title>Performance Evaluation on Simulated Data</title>
      <p>To rigorously compare BlackSheep to EdgeR<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> and Limma,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> we generated several sets of simulated data that recapitulate challenging
patterns found in real-world data sets, such as molecular data from cancer samples. Often,
researchers are interested in finding molecules that are enriched in a small subgroup
within a cohort. To address this common problem, we created simulated cohorts of 100
samples with 400 features each, split into an in-group and out-group of 12 and 88 samples,
respectively (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,B). Features for these
cohorts were pulled from Gaussian distributions with standard deviations of 1. All
features for the out-group were sampled from a distribution with a mean of 0, and we
varied the mean of the in-group distribution between 2, 1.5, 1, 0.5, and 0. We then tested
all features for differences between the in- and out-groups using DEVA, EdgeR, and Limma
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A). DEVA outperformed the other tools
for small but not large mean differences. With a mean difference of 0.5, Limma and EdgeR
do not have the power to detect differences between groups of 12 and 88 samples.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Comparison of DEVA with EdgeR and Limma for simulated samples. The top panels show
feature values for samples in each group. The bottom panels show ROC curves for each
tested tool. (A) 88 out-group and 12 in-group samples were generated with 400 features
each by sampling from Gaussian distributions with standard deviations of 1. Out-group
means are 0; in-group means are as indicated. (B) For the simulated cohort with a mean
difference of 2, increasing numbers of samples were swapped between the in- and
out-groups to simulate imperfect labeling or heterogeneity.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_0002" id="gr2" position="float"/>
      </fig>
      <p>We then set out to create a data set that would simulate the heterogeneous nature and
imperfect labeling of molecular cancer data. Tumors are notoriously difficult to classify.
In cancer data sets, subgroups often represent mixtures of molecular groups (e.g., luminal
breast cancer containing both A and B subtypes), and samples can easily be misclassified
(e.g., a Her2-enriched breast cancer sample mislabeled as luminal B). Subgroups used for
comparisons therefore often contain mixtures of samples with varying levels of enrichment
for a given feature. Because of the high variation of that feature within a group of
interest, many differential expression methods will be unable to detect that enrichment.
To simulate such a situation, we used our previously generated simulated data set with an
in-group mean of 2. Within that data set, we swapped increasing numbers of samples between
the in- and out-groups (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B). With
increasing levels of impurity between the groups, DEVA strongly outperformed the other two
tools. The above pattern of performance is not specific to the group sizes used in the
simulations. The same pattern was replicated with other sizes of imbalanced groups (data
not shown).</p>
    </sec>
    <sec id="sec3.2">
      <title>Application to Breast Cancer Cohort</title>
      <p>Reproducibly hyperphosphorylated kinases within a specific subtype or patient cohort
represent attractive targets for future drug development and
repurposing.<sup><xref ref-type="bibr" rid="ref19">19</xref>−<xref ref-type="bibr" rid="ref24">24</xref></sup> To demonstrate the utility of BlackSheep, we
applied it to a data set from a proteogenomic breast cancer study<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> to
find putatively overactive kinases that are unique to a molecular
subtype.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup> We also compared the results of BlackSheep to the commonly used
rank-sum test on real data. We used both tools to identify differentially abundant
phosphosites in Her2-enriched (Her2e) breast cancer samples as compared with all other
samples (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). In this cohort, Her2e is the
smallest group, comprising 12 of the 76 samples. We used the full phosphosite expression
matrix (63 130 phosphosites on 9881 proteins). Results of BlackSheep and the
rank-sum test were corrected for multiple hypotheses with equal stringency. At an FDR
cutoff of 0.01, rank-sum identified one enriched phosphosite (ERBB2-T1240) on the Her2
(ERBB2) protein (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>). The DEVA pipeline
identified 10 additional phosphosites on ERBB2 as well as phosphosites on established
coamplicons and modulators of Her2 signaling, such as GRB7<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref28">28</xref></sup> (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). BlackSheep does not identify features that
are enriched in large fractions of samples within a cohort. A feature with consistently
high or low values in a large fraction of the cohort will increase the median and the IQR
and will no longer be called an outlier. For small groups within a cohort, BlackSheep is
able to identify enriched features (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Comparing BlackSheep and rank-sum tests. Signed log<sub>10</sub><italic>q</italic> values from blacksheep.deva and rank-sum tests when comparing
normalized values in Her2e against all other samples using phospho data. Dotted lines
indicate FDR &lt; 0.01.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_0003" id="gr3" position="float"/>
      </fig>
      <fig id="fig4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Expression of phosphosites in the Her2 signaling pathway. <italic>Z</italic> scores
of relative log<sub>2</sub> abundance of all phosphosites in the Her2 signaling
pathway with FDR &lt; 0.01 calculated by BlackSheep.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_0004" id="gr4" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Conclusions</title>
    <p>Several cancer types have patients that fall into rare subgroups with worse prognoses than
the majority of patients (e.g., the serous subgroup in endometrial cancer or the basal-like
subgroup in breast cancer). Because of the difficulty in acquiring sufficient numbers of
samples, these patients are the hardest to study, yet they are the patients most in need of
new therapies. Whereas standard analysis techniques are useful for finding outliers that are
enriched in large subgroups of samples, these strategies often lack the power to find the
same for small subgroups. BlackSheep provides a user-friendly, complementary method to
delineate enrichments of outlier events in a small group of samples within a cohort. We show
that BlackSheep can find enrichment of known markers for small groups of samples, such as
ERBB2 and GRB7 in Her2e samples, which other commonly used analysis paradigms miss.
BlackSheep is a flexible complement to other methods such as rank-sum tests, EdgeR, and
Limma. Whereas the necessary cohort and group-of-interest sizes depend on the effect size a
user would like to detect, our simulations show that BlackSheep is highly sensitive and
specific for detecting enriched molecules in small groups of interest. BlackSheep has
previously been used to successfully detect druggable target kinases in small subgroups or
even single samples within small cohorts.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup> In the future,
BlackSheep-like strategies can be applied in the clinic to design and interpret diagnostic
panels applied to single tumors, to highlight targets of drugs that can be repurposed for
new indications, and to devise personalized treatments by prioritizing drugs that target
significant outliers in a tumor.</p>
  </sec>
</body>
<back>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jproteome.1c00190?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.1c00190</ext-link>.<list id="silist" list-type="simple"><list-item><p>Table S1: Example input files for DEVA: (A) Data
expression matrix and (B) sample annotation file for DEVA analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_002.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Table S2: Example output files from
DEVA: (A,B) Outliers output matrix, (C,D) the fracTable, (E,F) a significance output
file, (G,H) a table of outlier counts, <italic>p</italic> values, and
<italic>q</italic> values for the Her2 comparison (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_003.xlsx">XLSX</ext-link>)</p></list-item><list-item><p>Table S3: Example Output from
run_simulations: <italic>p</italic> values associated with each parent molecule (e.g.
gene) for each sample (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.1c00190/suppl_file/pr1c00190_si_004.xlsx">XLSX</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile2">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_si_002.xlsx">
        <caption>
          <p>pr1c00190_si_002.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile3">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_si_003.xlsx">
        <caption>
          <p>pr1c00190_si_003.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="sifile4">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr1c00190_si_004.xlsx">
        <caption>
          <p>pr1c00190_si_004.xlsx</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p><sup>⊥</sup> L.B., E.A.K., and M.C. contributed equally to this work</p>
  </notes>
  <notes notes-type="COI-statement" id="notes4">
    <p>The authors declare the following competing financial interest(s): K.V.R. serves on the
Scientific Advisory Board and consults for Netrias Data Solutions. D.F. is the Founder and
President of The Informatics Factory and serves or served on the Scientific Advisory Board
or consults for: Spectragen Informatics, Protein Metrics, Proteome Software, and
Preverna.</p>
  </notes>
  <notes notes-type="" id="notes-999">
    <title>Notes</title>
    <p>BlackSheep is available from Bioconductor (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bioconductor.org/packages/release/bioc/html/blacksheepr.html">https://www.bioconductor.org/packages/release/bioc/html/blacksheepr.html</uri>) and
Bioconda (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioconda.github.io/recipes/blksheep/README.html">https://bioconda.github.io/recipes/blksheep/README.html</uri>).</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>This work has used computing resources at the NYU High Performance Computing Facility
(HPCF). This work has been supported by the National Cancer Institute (NCI) through CPTAC
award U24 CA210972.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Mertins</surname><given-names>P.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Ruggles</surname><given-names>K. V.</given-names></name>; <name><surname>Gillette</surname><given-names>M. A.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Qiao</surname><given-names>J. W.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>; <name><surname>Petralia</surname><given-names>F.</given-names></name>; <name><surname>Kawaler</surname><given-names>E.</given-names></name>; <name><surname>Mundt</surname><given-names>F.</given-names></name>; <name><surname>Krug</surname><given-names>K.</given-names></name>; <name><surname>Tu</surname><given-names>Z.</given-names></name>; <name><surname>Lei</surname><given-names>J. T.</given-names></name>; <name><surname>Gatza</surname><given-names>M. L.</given-names></name>; <name><surname>Wilkerson</surname><given-names>M.</given-names></name>; <name><surname>Perou</surname><given-names>C. M.</given-names></name>; <name><surname>Yellapantula</surname><given-names>V.</given-names></name>; <name><surname>Huang</surname><given-names>K.-L.</given-names></name>; <name><surname>Lin</surname><given-names>C.</given-names></name>; <name><surname>McLellan</surname><given-names>M. D.</given-names></name>; <name><surname>Yan</surname><given-names>P.</given-names></name>; <name><surname>Davies</surname><given-names>S. R.</given-names></name>; <name><surname>Townsend</surname><given-names>R. R.</given-names></name>; <name><surname>Skates</surname><given-names>S. J.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Paulovich</surname><given-names>A. G.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <article-title>Proteogenomics Connects Somatic Mutations to Signalling in Breast
Cancer</article-title>. <source>Nature</source><year>2016</year>, <volume>534</volume> (<issue>7605</issue>), <fpage>55</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nature18003</pub-id>.<pub-id pub-id-type="pmid">27251275</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Payne</surname><given-names>S. H.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>McDermott</surname><given-names>J. E.</given-names></name>; <name><surname>Zhou</surname><given-names>J.-Y.</given-names></name>; <name><surname>Petyuk</surname><given-names>V. A.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Ray</surname><given-names>D.</given-names></name>; <name><surname>Sun</surname><given-names>S.</given-names></name>; <name><surname>Yang</surname><given-names>F.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Shah</surname><given-names>P.</given-names></name>; <name><surname>Cha</surname><given-names>S. W.</given-names></name>; <name><surname>Aiyetan</surname><given-names>P.</given-names></name>; <name><surname>Woo</surname><given-names>S.</given-names></name>; <name><surname>Tian</surname><given-names>Y.</given-names></name>; <name><surname>Gritsenko</surname><given-names>M. A.</given-names></name>; <name><surname>Clauss</surname><given-names>T. R.</given-names></name>; <name><surname>Choi</surname><given-names>C.</given-names></name>; <name><surname>Monroe</surname><given-names>M. E.</given-names></name>; <name><surname>Thomas</surname><given-names>S.</given-names></name>; <name><surname>Nie</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>C.</given-names></name>; <name><surname>Moore</surname><given-names>R. J.</given-names></name>; <name><surname>Yu</surname><given-names>K.-H.</given-names></name>; <name><surname>Tabb</surname><given-names>D. L.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Bafna</surname><given-names>V.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Boja</surname><given-names>E. S.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Rivers</surname><given-names>R. C.</given-names></name>; <name><surname>Sokoll</surname><given-names>L.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Shih</surname><given-names>I.-M.</given-names></name>; <name><surname>Cope</surname><given-names>L.</given-names></name>; <name><surname>Pandey</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Snyder</surname><given-names>M. P.</given-names></name>; <name><surname>Levine</surname><given-names>D. A.</given-names></name>; <name><surname>Smith</surname><given-names>R. D.</given-names></name>; <name><surname>Chan</surname><given-names>D. W.</given-names></name>; <name><surname>Rodland</surname><given-names>K. D.</given-names></name>; et al. <article-title>Integrated Proteogenomic Characterization of Human High-Grade Serous
Ovarian Cancer</article-title>. <source>Cell</source><year>2016</year>, <volume>166</volume> (<issue>3</issue>), <fpage>755</fpage>–<lpage>765</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.05.069</pub-id>.<pub-id pub-id-type="pmid">27372738</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Chambers</surname><given-names>M. C.</given-names></name>; <name><surname>Zimmerman</surname><given-names>L. J.</given-names></name>; <name><surname>Shaddox</surname><given-names>K. F.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Davies</surname><given-names>S. R.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Rivers</surname><given-names>R. C.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Townsend</surname><given-names>R. R.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J. C.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>Tabb</surname><given-names>D. L.</given-names></name>; <name><surname>Coffey</surname><given-names>R. J.</given-names></name>; <name><surname>Slebos</surname><given-names>R. J. C.</given-names></name>; <name><surname>Liebler</surname><given-names>D. C.</given-names></name>; <article-title>Proteogenomic Characterization of Human Colon and Rectal
Cancer</article-title>. <source>Nature</source><year>2014</year>, <volume>513</volume> (<issue>7518</issue>), <fpage>382</fpage>–<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1038/nature13438</pub-id>.<pub-id pub-id-type="pmid">25043054</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Huang</surname><given-names>K.-L.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Mertins</surname><given-names>P.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>; <name><surname>Gunawardena</surname><given-names>H. P.</given-names></name>; <name><surname>Ruggles</surname><given-names>K. V.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Tanioka</surname><given-names>M.</given-names></name>; <name><surname>Usary</surname><given-names>J.</given-names></name>; <name><surname>Kavuri</surname><given-names>S. M.</given-names></name>; <name><surname>Xie</surname><given-names>L.</given-names></name>; <name><surname>Yoon</surname><given-names>C.</given-names></name>; <name><surname>Qiao</surname><given-names>J. W.</given-names></name>; <name><surname>Wrobel</surname><given-names>J.</given-names></name>; <name><surname>Wyczalkowski</surname><given-names>M. A.</given-names></name>; <name><surname>Erdmann-Gilmore</surname><given-names>P.</given-names></name>; <name><surname>Snider</surname><given-names>J. E.</given-names></name>; <name><surname>Hoog</surname><given-names>J.</given-names></name>; <name><surname>Singh</surname><given-names>P.</given-names></name>; <name><surname>Niu</surname><given-names>B.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Sun</surname><given-names>S. Q.</given-names></name>; <name><surname>Sanati</surname><given-names>S.</given-names></name>; <name><surname>Kawaler</surname><given-names>E.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Scott</surname><given-names>A.</given-names></name>; <name><surname>Ye</surname><given-names>K.</given-names></name>; <name><surname>McLellan</surname><given-names>M. D.</given-names></name>; <name><surname>Wendl</surname><given-names>M. C.</given-names></name>; <name><surname>Malovannaya</surname><given-names>A.</given-names></name>; <name><surname>Held</surname><given-names>J. M.</given-names></name>; <name><surname>Gillette</surname><given-names>M. A.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Davies</surname><given-names>S. R.</given-names></name>; <name><surname>Perou</surname><given-names>C. M.</given-names></name>; <name><surname>Ma</surname><given-names>C.</given-names></name>; <name><surname>Reid Townsend</surname><given-names>R.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name><article-title>Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer
Xenografts</article-title>. <source>Nat. Commun.</source><year>2017</year>, <volume>8</volume>, <fpage>14864</fpage><pub-id pub-id-type="doi">10.1038/ncomms14864</pub-id>.<pub-id pub-id-type="pmid">28348404</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Mun</surname><given-names>D.-G.</given-names></name>; <name><surname>Bhin</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>H.</given-names></name>; <name><surname>Jung</surname><given-names>J. H.</given-names></name>; <name><surname>Jung</surname><given-names>Y.</given-names></name>; <name><surname>Jang</surname><given-names>Y. E.</given-names></name>; <name><surname>Park</surname><given-names>J. M.</given-names></name>; <name><surname>Kim</surname><given-names>H.</given-names></name>; <name><surname>Jung</surname><given-names>Y.</given-names></name>; <name><surname>Lee</surname><given-names>H.</given-names></name>; <name><surname>Bae</surname><given-names>J.</given-names></name>; <name><surname>Back</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>S.-J.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Park</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Hwang</surname><given-names>K.-B.</given-names></name>; <name><surname>Park</surname><given-names>Y. S.</given-names></name>; <name><surname>Yook</surname><given-names>J. H.</given-names></name>; <name><surname>Kim</surname><given-names>B. S.</given-names></name>; <name><surname>Kwon</surname><given-names>S. Y.</given-names></name>; <name><surname>Ryu</surname><given-names>S. W.</given-names></name>; <name><surname>Park</surname><given-names>D. Y.</given-names></name>; <name><surname>Jeon</surname><given-names>T. Y.</given-names></name>; <name><surname>Kim</surname><given-names>D. H.</given-names></name>; <name><surname>Lee</surname><given-names>J.-H.</given-names></name>; <name><surname>Han</surname><given-names>S.-U.</given-names></name>; <name><surname>Song</surname><given-names>K. S.</given-names></name>; <name><surname>Park</surname><given-names>D.</given-names></name>; <name><surname>Park</surname><given-names>J. W.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Lee</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>K. P.</given-names></name>; <name><surname>Yang</surname><given-names>E. G.</given-names></name>; <name><surname>Kim</surname><given-names>H. K.</given-names></name>; <name><surname>Paek</surname><given-names>E.</given-names></name>; <name><surname>Lee</surname><given-names>S.</given-names></name>; <name><surname>Lee</surname><given-names>S.-W.</given-names></name>; <name><surname>Hwang</surname><given-names>D.</given-names></name><article-title>Proteogenomic Characterization of Human Early-Onset Gastric
Cancer</article-title>. <source>Cancer Cell</source><year>2019</year>, <volume>35</volume> (<issue>1</issue>), <fpage>111</fpage>–<lpage>124.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2018.12.003</pub-id>.<pub-id pub-id-type="pmid">30645970</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Vasaikar</surname><given-names>S.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Petyuk</surname><given-names>V. A.</given-names></name>; <name><surname>Savage</surname><given-names>S. R.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Dou</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Arshad</surname><given-names>O. A.</given-names></name>; <name><surname>Gritsenko</surname><given-names>M. A.</given-names></name>; <name><surname>Zimmerman</surname><given-names>L. J.</given-names></name>; <name><surname>McDermott</surname><given-names>J. E.</given-names></name>; <name><surname>Clauss</surname><given-names>T. R.</given-names></name>; <name><surname>Moore</surname><given-names>R. J.</given-names></name>; <name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Monroe</surname><given-names>M. E.</given-names></name>; <name><surname>Wang</surname><given-names>Y.-T.</given-names></name>; <name><surname>Chambers</surname><given-names>M. C.</given-names></name>; <name><surname>Slebos</surname><given-names>R. J.C.</given-names></name>; <name><surname>Lau</surname><given-names>K. S.</given-names></name>; <name><surname>Mo</surname><given-names>Q.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Ellis</surname><given-names>M.</given-names></name>; <name><surname>Thiagarajan</surname><given-names>M.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Smith</surname><given-names>R. D.</given-names></name>; <name><surname>Rodland</surname><given-names>K. D.</given-names></name>; <name><surname>Liebler</surname><given-names>D. C.</given-names></name>; <name><surname>Liu</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Pandey</surname><given-names>A.</given-names></name>; <name><surname>Paulovich</surname><given-names>A.</given-names></name>; <name><surname>Hoofnagle</surname><given-names>A.</given-names></name>; <name><surname>Mani</surname><given-names>D.R.</given-names></name>; <name><surname>Chan</surname><given-names>D. W.</given-names></name>; <name><surname>Ransohoff</surname><given-names>D. F.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Tabb</surname><given-names>D. L.</given-names></name>; <name><surname>Levine</surname><given-names>D. A.</given-names></name>; <name><surname>Boja</surname><given-names>E. S.</given-names></name>; <name><surname>Kuhn</surname><given-names>E.</given-names></name>; <name><surname>White</surname><given-names>F. M.</given-names></name>; <name><surname>Whiteley</surname><given-names>G. A.</given-names></name>; <name><surname>Zhu</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Shih</surname><given-names>I.-M.</given-names></name>; <name><surname>Bavarva</surname><given-names>J.</given-names></name>; <name><surname>Whiteaker</surname><given-names>J.</given-names></name>; <name><surname>Ketchum</surname><given-names>K. A.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Ruggles</surname><given-names>K.</given-names></name>; <name><surname>Elburn</surname><given-names>K.</given-names></name>; <name><surname>Hannick</surname><given-names>L.</given-names></name>; <name><surname>Watson</surname><given-names>M.</given-names></name>; <name><surname>Oberti</surname><given-names>M.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Sanders</surname><given-names>M. E.</given-names></name>; <name><surname>Borucki</surname><given-names>M.</given-names></name>; <name><surname>Gillette</surname><given-names>M. A.</given-names></name>; <name><surname>Snyder</surname><given-names>M.</given-names></name>; <name><surname>Edwards</surname><given-names>N. J.</given-names></name>; <name><surname>Vatanian</surname><given-names>N.</given-names></name>; <name><surname>Rudnick</surname><given-names>P. A.</given-names></name>; <name><surname>McGarvey</surname><given-names>P. B.</given-names></name>; <name><surname>Mertins</surname><given-names>P.</given-names></name>; <name><surname>Townsend</surname><given-names>R. R.</given-names></name>; <name><surname>Thangudu</surname><given-names>R. R.</given-names></name>; <name><surname>Rivers</surname><given-names>R. C.</given-names></name>; <name><surname>Payne</surname><given-names>S. H.</given-names></name>; <name><surname>Davies</surname><given-names>S. R.</given-names></name>; <name><surname>Cai</surname><given-names>S.</given-names></name>; <name><surname>Stein</surname><given-names>S. E.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>Skates</surname><given-names>S. J.</given-names></name>; <name><surname>Madhavan</surname><given-names>S.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name><article-title>Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic
Opportunities</article-title>. <source>Cell</source><year>2019</year>, <volume>177</volume> (<issue>4</issue>), <fpage>1035</fpage>–<lpage>1049.e19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.03.030</pub-id>.<pub-id pub-id-type="pmid">31031003</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Sinha</surname><given-names>A.</given-names></name>; <name><surname>Huang</surname><given-names>V.</given-names></name>; <name><surname>Livingstone</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Fox</surname><given-names>N. S.</given-names></name>; <name><surname>Kurganovs</surname><given-names>N.</given-names></name>; <name><surname>Ignatchenko</surname><given-names>V.</given-names></name>; <name><surname>Fritsch</surname><given-names>K.</given-names></name>; <name><surname>Donmez</surname><given-names>N.</given-names></name>; <name><surname>Heisler</surname><given-names>L. E.</given-names></name>; <name><surname>Shiah</surname><given-names>Y.-J.</given-names></name>; <name><surname>Yao</surname><given-names>C. Q.</given-names></name>; <name><surname>Alfaro</surname><given-names>J. A.</given-names></name>; <name><surname>Volik</surname><given-names>S.</given-names></name>; <name><surname>Lapuk</surname><given-names>A.</given-names></name>; <name><surname>Fraser</surname><given-names>M.</given-names></name>; <name><surname>Kron</surname><given-names>K.</given-names></name>; <name><surname>Murison</surname><given-names>A.</given-names></name>; <name><surname>Lupien</surname><given-names>M.</given-names></name>; <name><surname>Sahinalp</surname><given-names>C.</given-names></name>; <name><surname>Collins</surname><given-names>C. C.</given-names></name>; <name><surname>Tetu</surname><given-names>B.</given-names></name>; <name><surname>Masoomian</surname><given-names>M.</given-names></name>; <name><surname>Berman</surname><given-names>D. M.</given-names></name>; <name><surname>van der Kwast</surname><given-names>T.</given-names></name>; <name><surname>Bristow</surname><given-names>R. G.</given-names></name>; <name><surname>Kislinger</surname><given-names>T.</given-names></name>; <name><surname>Boutros</surname><given-names>P. C.</given-names></name><article-title>The Proteogenomic Landscape of Curable Prostate Cancer</article-title>. <source>Cancer Cell</source><year>2019</year>, <volume>35</volume> (<issue>3</issue>), <fpage>414</fpage>–<lpage>427.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2019.02.005</pub-id>.<pub-id pub-id-type="pmid">30889379</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Savage</surname><given-names>S. R.</given-names></name>; <name><surname>Eguez</surname><given-names>R. V.</given-names></name>; <name><surname>Dou</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>da Veiga Leprevost</surname><given-names>F.</given-names></name>; <name><surname>Jaehnig</surname><given-names>E. J.</given-names></name>; <name><surname>Lei</surname><given-names>J. T.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Schnaubelt</surname><given-names>M.</given-names></name>; <name><surname>Krug</surname><given-names>K.</given-names></name>; <name><surname>Song</surname><given-names>X.</given-names></name>; <name><surname>Cieślik</surname><given-names>M.</given-names></name>; <name><surname>Chang</surname><given-names>H.-Y.</given-names></name>; <name><surname>Wyczalkowski</surname><given-names>M. A.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Colaprico</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>Q. K.</given-names></name>; <name><surname>Clark</surname><given-names>D. J.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Cao</surname><given-names>L.</given-names></name>; <name><surname>Pan</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Cho</surname><given-names>K.-C.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Liao</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>W.</given-names></name>; <name><surname>Anurag</surname><given-names>M.</given-names></name>; <name><surname>Ji</surname><given-names>J.</given-names></name>; <name><surname>Yoo</surname><given-names>S.</given-names></name>; <name><surname>Zhou</surname><given-names>D. C.</given-names></name>; <name><surname>Liang</surname><given-names>W.-W.</given-names></name>; <name><surname>Wendl</surname><given-names>M.</given-names></name>; <name><surname>Vats</surname><given-names>P.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Qian</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>X. S.</given-names></name>; <name><surname>Pico</surname><given-names>A. R.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Chinnaiyan</surname><given-names>A. M.</given-names></name>; <name><surname>Ketchum</surname><given-names>K. A.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Robles</surname><given-names>A. I.</given-names></name>; <name><surname>An</surname><given-names>E.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Thiagarajan</surname><given-names>M.</given-names></name>; <name><surname>Weaver</surname><given-names>A. M.</given-names></name>; <name><surname>Sikora</surname><given-names>A. G.</given-names></name>; <name><surname>Lubiński</surname><given-names>J.</given-names></name>; <name><surname>Wierzbicka</surname><given-names>M.</given-names></name>; <name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>; <name><surname>Satpathy</surname><given-names>S.</given-names></name>; <name><surname>Gillette</surname><given-names>M. A.</given-names></name>; <name><surname>Miles</surname><given-names>G.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>Omenn</surname><given-names>G. S.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Boja</surname><given-names>E. S.</given-names></name>; <name><surname>Dhanasekaran</surname><given-names>S. M.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name>; <name><surname>El-Naggar</surname><given-names>A. K.</given-names></name>; <name><surname>Chan</surname><given-names>D. W.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; et al. <article-title>Proteogenomic Insights into the Biology and Treatment of HPV-Negative Head
and Neck Squamous Cell Carcinoma</article-title>. <source>Cancer Cell</source><year>2021</year>, <volume>39</volume> (<issue>3</issue>), <fpage>361</fpage>–<lpage>379.e16</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2020.12.007</pub-id>.<pub-id pub-id-type="pmid">33417831</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Krug</surname><given-names>K.</given-names></name>; <name><surname>Jaehnig</surname><given-names>E. J.</given-names></name>; <name><surname>Satpathy</surname><given-names>S.</given-names></name>; <name><surname>Blumenberg</surname><given-names>L.</given-names></name>; <name><surname>Karpova</surname><given-names>A.</given-names></name>; <name><surname>Anurag</surname><given-names>M.</given-names></name>; <name><surname>Miles</surname><given-names>G.</given-names></name>; <name><surname>Mertins</surname><given-names>P.</given-names></name>; <name><surname>Geffen</surname><given-names>Y.</given-names></name>; <name><surname>Tang</surname><given-names>L. C.</given-names></name>; <name><surname>Heiman</surname><given-names>D. I.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>; <name><surname>Maruvka</surname><given-names>Y. E.</given-names></name>; <name><surname>Lei</surname><given-names>J. T.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Kothadia</surname><given-names>R. B.</given-names></name>; <name><surname>Colaprico</surname><given-names>A.</given-names></name>; <name><surname>Birger</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Dou</surname><given-names>Y.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Liao</surname><given-names>Y.</given-names></name>; <name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>; <name><surname>Wyczalkowski</surname><given-names>M. A.</given-names></name>; <name><surname>Chen</surname><given-names>X. S.</given-names></name>; <name><surname>Kennedy</surname><given-names>J. J.</given-names></name>; <name><surname>Paulovich</surname><given-names>A. G.</given-names></name>; <name><surname>Thiagarajan</surname><given-names>M.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Boja</surname><given-names>E. S.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Robles</surname><given-names>A. I.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Westbrook</surname><given-names>T. F.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Getz</surname><given-names>G.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Ruggles</surname><given-names>K. V.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>Gillette</surname><given-names>M. A.</given-names></name>; et al. <article-title>Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted
Therapy</article-title>. <source>Cell</source><year>2020</year>, <volume>183</volume> (<issue>5</issue>), <fpage>1436</fpage>–<lpage>1456.e31</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.036</pub-id>.<pub-id pub-id-type="pmid">33212010</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Gillette</surname><given-names>M. A.</given-names></name>; <name><surname>Satpathy</surname><given-names>S.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>; <name><surname>Dhanasekaran</surname><given-names>S. M.</given-names></name>; <name><surname>Vasaikar</surname><given-names>S. V.</given-names></name>; <name><surname>Krug</surname><given-names>K.</given-names></name>; <name><surname>Petralia</surname><given-names>F.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Liang</surname><given-names>W.-W.</given-names></name>; <name><surname>Reva</surname><given-names>B.</given-names></name>; <name><surname>Krek</surname><given-names>A.</given-names></name>; <name><surname>Ji</surname><given-names>J.</given-names></name>; <name><surname>Song</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Hong</surname><given-names>R.</given-names></name>; <name><surname>Yao</surname><given-names>L.</given-names></name>; <name><surname>Blumenberg</surname><given-names>L.</given-names></name>; <name><surname>Savage</surname><given-names>S. R.</given-names></name>; <name><surname>Wendl</surname><given-names>M. C.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Tang</surname><given-names>L. C.</given-names></name>; <name><surname>MacMullan</surname><given-names>M. A.</given-names></name>; <name><surname>Avanessian</surname><given-names>S. C.</given-names></name>; <name><surname>Kane</surname><given-names>M. H.</given-names></name>; <name><surname>Newton</surname><given-names>C. J.</given-names></name>; <name><surname>Cornwell</surname><given-names>M.</given-names></name>; <name><surname>Kothadia</surname><given-names>R. B.</given-names></name>; <name><surname>Ma</surname><given-names>W.</given-names></name>; <name><surname>Yoo</surname><given-names>S.</given-names></name>; <name><surname>Mannan</surname><given-names>R.</given-names></name>; <name><surname>Vats</surname><given-names>P.</given-names></name>; <name><surname>Kumar-Sinha</surname><given-names>C.</given-names></name>; <name><surname>Kawaler</surname><given-names>E. A.</given-names></name>; <name><surname>Omelchenko</surname><given-names>T.</given-names></name>; <name><surname>Colaprico</surname><given-names>A.</given-names></name>; <name><surname>Geffen</surname><given-names>Y.</given-names></name>; <name><surname>Maruvka</surname><given-names>Y. E.</given-names></name>; <name><surname>da Veiga Leprevost</surname><given-names>F.</given-names></name>; <name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>; <name><surname>Gümüş</surname><given-names>Z. H.</given-names></name>; <name><surname>Veluswamy</surname><given-names>R. R.</given-names></name>; <name><surname>Hostetter</surname><given-names>G.</given-names></name>; <name><surname>Heiman</surname><given-names>D. I.</given-names></name>; <name><surname>Wyczalkowski</surname><given-names>M. A.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Boja</surname><given-names>E. S.</given-names></name>; <name><surname>Omenn</surname><given-names>G. S.</given-names></name>; <name><surname>Chinnaiyan</surname><given-names>A. M.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>Q. K.</given-names></name>; <name><surname>Jewell</surname><given-names>S. D.</given-names></name>; <name><surname>Thiagarajan</surname><given-names>M.</given-names></name>; <name><surname>Getz</surname><given-names>G.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Ruggles</surname><given-names>K. V.</given-names></name>; <name><surname>Cieslik</surname><given-names>M. P.</given-names></name>; <name><surname>Robles</surname><given-names>A. I.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Govindan</surname><given-names>R.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; et al. <article-title>Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung
Adenocarcinoma</article-title>. <source>Cell</source><year>2020</year>, <volume>182</volume> (<issue>1</issue>), <fpage>200</fpage>–<lpage>225.e35</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.06.013</pub-id>.<pub-id pub-id-type="pmid">32649874</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Dou</surname><given-names>Y.</given-names></name>; <name><surname>Kawaler</surname><given-names>E. A.</given-names></name>; <name><surname>Cui Zhou</surname><given-names>D.</given-names></name>; <name><surname>Gritsenko</surname><given-names>M. A.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Blumenberg</surname><given-names>L.</given-names></name>; <name><surname>Karpova</surname><given-names>A.</given-names></name>; <name><surname>Petyuk</surname><given-names>V. A.</given-names></name>; <name><surname>Savage</surname><given-names>S. R.</given-names></name>; <name><surname>Satpathy</surname><given-names>S.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Tsai</surname><given-names>C.-F.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>; <name><surname>Moon</surname><given-names>J.</given-names></name>; <name><surname>Shi</surname><given-names>Z.</given-names></name>; <name><surname>Cornwell</surname><given-names>M.</given-names></name>; <name><surname>Wyczalkowski</surname><given-names>M. A.</given-names></name>; <name><surname>Chu</surname><given-names>R. K.</given-names></name>; <name><surname>Vasaikar</surname><given-names>S.</given-names></name>; <name><surname>Zhou</surname><given-names>H.</given-names></name>; <name><surname>Gao</surname><given-names>Q.</given-names></name>; <name><surname>Moore</surname><given-names>R. J.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Sethuraman</surname><given-names>S.</given-names></name>; <name><surname>Monroe</surname><given-names>M. E.</given-names></name>; <name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Heiman</surname><given-names>D.</given-names></name>; <name><surname>Krug</surname><given-names>K.</given-names></name>; <name><surname>Clauser</surname><given-names>K.</given-names></name>; <name><surname>Kothadia</surname><given-names>R.</given-names></name>; <name><surname>Maruvka</surname><given-names>Y.</given-names></name>; <name><surname>Pico</surname><given-names>A. R.</given-names></name>; <name><surname>Oliphant</surname><given-names>A. E.</given-names></name>; <name><surname>Hoskins</surname><given-names>E. L.</given-names></name>; <name><surname>Pugh</surname><given-names>S. L.</given-names></name>; <name><surname>Beecroft</surname><given-names>S. J. I.</given-names></name>; <name><surname>Adams</surname><given-names>D. W.</given-names></name>; <name><surname>Jarman</surname><given-names>J. C.</given-names></name>; <name><surname>Kong</surname><given-names>A.</given-names></name>; <name><surname>Chang</surname><given-names>H.-Y.</given-names></name>; <name><surname>Reva</surname><given-names>B.</given-names></name>; <name><surname>Liao</surname><given-names>Y.</given-names></name>; <name><surname>Rykunov</surname><given-names>D.</given-names></name>; <name><surname>Colaprico</surname><given-names>A.</given-names></name>; <name><surname>Chen</surname><given-names>X. S.</given-names></name>; <name><surname>Czekański</surname><given-names>A.</given-names></name>; <name><surname>Jȩdryka</surname><given-names>M.</given-names></name>; <name><surname>Matkowski</surname><given-names>R.</given-names></name>; <name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Boja</surname><given-names>E.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Robles</surname><given-names>A. I.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Mutch</surname><given-names>D.</given-names></name>; <name><surname>Fuh</surname><given-names>K.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>DeLair</surname><given-names>D.</given-names></name>; <name><surname>Thiagarajan</surname><given-names>M.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Getz</surname><given-names>G.</given-names></name>; <name><surname>Noble</surname><given-names>M.</given-names></name>; <name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Anderson</surname><given-names>M. L.</given-names></name>; <name><surname>Levine</surname><given-names>D. A.</given-names></name>; <name><surname>Smith</surname><given-names>R. D.</given-names></name>; <name><surname>Payne</surname><given-names>S. H.</given-names></name>; <name><surname>Ruggles</surname><given-names>K. V.</given-names></name>; <name><surname>Rodland</surname><given-names>K. D.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Liu</surname><given-names>T.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; et al. <article-title>Proteogenomic Characterization of Endometrial Carcinoma</article-title>. <source>Cell</source><year>2020</year>, <volume>180</volume> (<issue>4</issue>), <fpage>729</fpage>–<lpage>748.e26</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.01.026</pub-id>.<pub-id pub-id-type="pmid">32059776</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Clark</surname><given-names>D. J.</given-names></name>; <name><surname>Dhanasekaran</surname><given-names>S. M.</given-names></name>; <name><surname>Petralia</surname><given-names>F.</given-names></name>; <name><surname>Pan</surname><given-names>J.</given-names></name>; <name><surname>Song</surname><given-names>X.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>da Veiga Leprevost</surname><given-names>F.</given-names></name>; <name><surname>Reva</surname><given-names>B.</given-names></name>; <name><surname>Lih</surname><given-names>T.-S. M.</given-names></name>; <name><surname>Chang</surname><given-names>H.-Y.</given-names></name>; <name><surname>Ma</surname><given-names>W.</given-names></name>; <name><surname>Huang</surname><given-names>C.</given-names></name>; <name><surname>Ricketts</surname><given-names>C. J.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Krek</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Rykunov</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>Q. K.</given-names></name>; <name><surname>Chen</surname><given-names>L. S.</given-names></name>; <name><surname>Ozbek</surname><given-names>U.</given-names></name>; <name><surname>Vasaikar</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Yoo</surname><given-names>S.</given-names></name>; <name><surname>Chowdhury</surname><given-names>S.</given-names></name>; <name><surname>Wyczalkowski</surname><given-names>M. A.</given-names></name>; <name><surname>Ji</surname><given-names>J.</given-names></name>; <name><surname>Schnaubelt</surname><given-names>M.</given-names></name>; <name><surname>Kong</surname><given-names>A.</given-names></name>; <name><surname>Sethuraman</surname><given-names>S.</given-names></name>; <name><surname>Avtonomov</surname><given-names>D. M.</given-names></name>; <name><surname>Ao</surname><given-names>M.</given-names></name>; <name><surname>Colaprico</surname><given-names>A.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>; <name><surname>Cho</surname><given-names>K.-C.</given-names></name>; <name><surname>Kalayci</surname><given-names>S.</given-names></name>; <name><surname>Ma</surname><given-names>S.</given-names></name>; <name><surname>Liu</surname><given-names>W.</given-names></name>; <name><surname>Ruggles</surname><given-names>K.</given-names></name>; <name><surname>Calinawan</surname><given-names>A.</given-names></name>; <name><surname>Gümüş</surname><given-names>Z. H.</given-names></name>; <name><surname>Geiszler</surname><given-names>D.</given-names></name>; <name><surname>Kawaler</surname><given-names>E.</given-names></name>; <name><surname>Teo</surname><given-names>G. C.</given-names></name>; <name><surname>Wen</surname><given-names>B.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Keegan</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Chen</surname><given-names>F.</given-names></name>; <name><surname>Edwards</surname><given-names>N.</given-names></name>; <name><surname>Pierorazio</surname><given-names>P. M.</given-names></name>; <name><surname>Chen</surname><given-names>X. S.</given-names></name>; <name><surname>Pavlovich</surname><given-names>C. P.</given-names></name>; <name><surname>Hakimi</surname><given-names>A. A.</given-names></name>; <name><surname>Brominski</surname><given-names>G.</given-names></name>; <name><surname>Hsieh</surname><given-names>J. J.</given-names></name>; <name><surname>Antczak</surname><given-names>A.</given-names></name>; <name><surname>Omelchenko</surname><given-names>T.</given-names></name>; <name><surname>Lubinski</surname><given-names>J.</given-names></name>; <name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>; <name><surname>Linehan</surname><given-names>W. M.</given-names></name>; <name><surname>Kinsinger</surname><given-names>C. R.</given-names></name>; <name><surname>Thiagarajan</surname><given-names>M.</given-names></name>; <name><surname>Boja</surname><given-names>E. S.</given-names></name>; <name><surname>Mesri</surname><given-names>M.</given-names></name>; <name><surname>Hiltke</surname><given-names>T.</given-names></name>; <name><surname>Robles</surname><given-names>A. I.</given-names></name>; <name><surname>Rodriguez</surname><given-names>H.</given-names></name>; <name><surname>Qian</surname><given-names>J.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Schadt</surname><given-names>E.</given-names></name>; <name><surname>Chinnaiyan</surname><given-names>A. M.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Omenn</surname><given-names>G. S.</given-names></name>; <name><surname>Cieslik</surname><given-names>M.</given-names></name>; <name><surname>Chan</surname><given-names>D. W.</given-names></name>; <name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; et al. <article-title>Integrated Proteogenomic Characterization of Clear Cell Renal Cell
Carcinoma</article-title>. <source>Cell</source><year>2020</year>, <volume>179</volume> (<issue>4</issue>), <fpage>964</fpage>–<lpage>983.e31</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.12.026</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Mundt</surname><given-names>F.</given-names></name>; <name><surname>Rajput</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Ruggles</surname><given-names>K. V.</given-names></name>; <name><surname>Mooradian</surname><given-names>A. D.</given-names></name>; <name><surname>Mertins</surname><given-names>P.</given-names></name>; <name><surname>Gillette</surname><given-names>M. A.</given-names></name>; <name><surname>Krug</surname><given-names>K.</given-names></name>; <name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Hoog</surname><given-names>J.</given-names></name>; <name><surname>Erdmann-Gilmore</surname><given-names>P.</given-names></name>; <name><surname>Primeau</surname><given-names>T.</given-names></name>; <name><surname>Huang</surname><given-names>S.</given-names></name>; <name><surname>Edwards</surname><given-names>D. P.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Kawaler</surname><given-names>E.</given-names></name>; <name><surname>Mani</surname><given-names>D. R.</given-names></name>; <name><surname>Clauser</surname><given-names>K. R.</given-names></name>; <name><surname>Gao</surname><given-names>F.</given-names></name>; <name><surname>Luo</surname><given-names>J.</given-names></name>; <name><surname>Davies</surname><given-names>S. R.</given-names></name>; <name><surname>Johnson</surname><given-names>G. L.</given-names></name>; <name><surname>Huang</surname><given-names>K.-L.</given-names></name>; <name><surname>Yoon</surname><given-names>C. J.</given-names></name>; <name><surname>Ding</surname><given-names>L.</given-names></name>; <name><surname>Fenyö</surname><given-names>D.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>Townsend</surname><given-names>R. R.</given-names></name>; <name><surname>Held</surname><given-names>J. M.</given-names></name>; <name><surname>Carr</surname><given-names>S. A.</given-names></name>; <name><surname>Ma</surname><given-names>C. X.</given-names></name><article-title>Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and
MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast
Cancers</article-title>. <source>Cancer Res.</source><year>2018</year>, <volume>78</volume> (<issue>10</issue>), <fpage>2732</fpage>–<lpage>2746</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1990</pub-id>.<pub-id pub-id-type="pmid">29472518</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Sullivan</surname><given-names>G. M.</given-names></name>; <name><surname>Feinn</surname><given-names>R.</given-names></name><article-title>Using Effect Size-or Why the P Value Is Not Enough</article-title>. <source>J. Grad. Med. Educ.</source><year>2012</year>, <volume>4</volume> (<issue>3</issue>), <fpage>279</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.4300/JGME-D-12-00156.1</pub-id>.<pub-id pub-id-type="pmid">23997866</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Nakagawa</surname><given-names>S.</given-names></name>; <name><surname>Cuthill</surname><given-names>I. C.</given-names></name><article-title>Effect Size, Confidence Interval and Statistical Significance: A Practical
Guide for Biologists</article-title>. <source>Biol. Rev. Camb. Philos. Soc.</source><year>2007</year>, <volume>82</volume> (<issue>4</issue>), <fpage>591</fpage>–<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-185X.2007.00027.x</pub-id>.<pub-id pub-id-type="pmid">17944619</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Benjamini</surname><given-names>Y.</given-names></name>; <name><surname>Hochberg</surname><given-names>Y.</given-names></name><article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to
Multiple Testing</article-title>. <source>J. R. Stat. Soc. Series B Stat. Methodol.</source><year>1995</year>, <volume>57</volume> (<issue>1</issue>), <fpage>289</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Robinson</surname><given-names>M. D.</given-names></name>; <name><surname>McCarthy</surname><given-names>D. J.</given-names></name>; <name><surname>Smyth</surname><given-names>G. K.</given-names></name><article-title>edgeR: A Bioconductor Package for Differential Expression Analysis of
Digital Gene Expression Data</article-title>. <source>Bioinformatics</source><year>2010</year>, <volume>26</volume> (<issue>1</issue>), <fpage>139</fpage>–<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id>.<pub-id pub-id-type="pmid">19910308</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Ritchie</surname><given-names>M. E.</given-names></name>; <name><surname>Phipson</surname><given-names>B.</given-names></name>; <name><surname>Wu</surname><given-names>D.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Law</surname><given-names>C. W.</given-names></name>; <name><surname>Shi</surname><given-names>W.</given-names></name>; <name><surname>Smyth</surname><given-names>G. K.</given-names></name><article-title>Limma Powers Differential Expression Analyses for RNA-Sequencing and
Microarray Studies</article-title>. <source>Nucleic Acids Res.</source><year>2015</year>, <volume>43</volume> (<issue>7</issue>), <fpage>e47</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>.<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Hyman</surname><given-names>D. M.</given-names></name>; <name><surname>Puzanov</surname><given-names>I.</given-names></name>; <name><surname>Subbiah</surname><given-names>V.</given-names></name>; <name><surname>Faris</surname><given-names>J. E.</given-names></name>; <name><surname>Chau</surname><given-names>I.</given-names></name>; <name><surname>Blay</surname><given-names>J.-Y.</given-names></name>; <name><surname>Wolf</surname><given-names>J.</given-names></name>; <name><surname>Raje</surname><given-names>N. S.</given-names></name>; <name><surname>Diamond</surname><given-names>E. L.</given-names></name>; <name><surname>Hollebecque</surname><given-names>A.</given-names></name>; <name><surname>Gervais</surname><given-names>R.</given-names></name>; <name><surname>Elez-Fernandez</surname><given-names>M. E.</given-names></name>; <name><surname>Italiano</surname><given-names>A.</given-names></name>; <name><surname>Hofheinz</surname><given-names>R.-D.</given-names></name>; <name><surname>Hidalgo</surname><given-names>M.</given-names></name>; <name><surname>Chan</surname><given-names>E.</given-names></name>; <name><surname>Schuler</surname><given-names>M.</given-names></name>; <name><surname>Lasserre</surname><given-names>S. F.</given-names></name>; <name><surname>Makrutzki</surname><given-names>M.</given-names></name>; <name><surname>Sirzen</surname><given-names>F.</given-names></name>; <name><surname>Veronese</surname><given-names>M. L.</given-names></name>; <name><surname>Tabernero</surname><given-names>J.</given-names></name>; <name><surname>Baselga</surname><given-names>J.</given-names></name><article-title>Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600
Mutations</article-title>. <source>N. Engl. J. Med.</source><year>2015</year>, <volume>373</volume> (<issue>8</issue>), <fpage>726</fpage>–<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1502309</pub-id>.<pub-id pub-id-type="pmid">26287849</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><name><surname>Bollag</surname><given-names>G.</given-names></name>; <name><surname>Tsai</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>C.</given-names></name>; <name><surname>Ibrahim</surname><given-names>P.</given-names></name>; <name><surname>Nolop</surname><given-names>K.</given-names></name>; <name><surname>Hirth</surname><given-names>P.</given-names></name><article-title>Vemurafenib: The First Drug Approved for BRAF-Mutant Cancer</article-title>. <source>Nat. Rev. Drug Discovery</source><year>2012</year>, <volume>11</volume> (<issue>11</issue>), <fpage>873</fpage>–<lpage>886</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3847</pub-id>.<pub-id pub-id-type="pmid">23060265</pub-id></mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Qin</surname><given-names>T.</given-names></name>; <name><surname>Yuan</surname><given-names>Z.</given-names></name>; <name><surname>Peng</surname><given-names>R.</given-names></name>; <name><surname>Bai</surname><given-names>B.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Teng</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name><article-title>HER2-Positive Breast Cancer Patients Receiving Trastuzumab Treatment Obtain
Prognosis Comparable with that of HER2-Negative Breast Cancer Patients</article-title>. <source>OncoTargets Ther.</source><year>2013</year>, <volume>6</volume>, <fpage>341</fpage>–<lpage>347</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S40851</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Soverini</surname><given-names>S.</given-names></name>; <name><surname>Mancini</surname><given-names>M.</given-names></name>; <name><surname>Bavaro</surname><given-names>L.</given-names></name>; <name><surname>Cavo</surname><given-names>M.</given-names></name>; <name><surname>Martinelli</surname><given-names>G.</given-names></name><article-title>Chronic Myeloid Leukemia: The Paradigm of Targeting Oncogenic Tyrosine
Kinase Signaling and Counteracting Resistance for Successful Cancer
Therapy</article-title>. <source>Mol. Cancer</source><year>2018</year>, <volume>17</volume> (<issue>1</issue>), <fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0780-6</pub-id>.<pub-id pub-id-type="pmid">29455643</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <mixed-citation publication-type="journal" id="cit23"><name><surname>Hantschel</surname><given-names>O.</given-names></name><article-title>Structure, Regulation, Signaling, and Targeting of Abl Kinases in
Cancer</article-title>. <source>Genes Cancer</source><year>2012</year>, <volume>3</volume> (<issue>5–6</issue>), <fpage>436</fpage>–<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1177/1947601912458584</pub-id>.<pub-id pub-id-type="pmid">23226581</pub-id></mixed-citation>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Hochhaus</surname><given-names>A.</given-names></name>; <name><surname>Larson</surname><given-names>R. A.</given-names></name>; <name><surname>Guilhot</surname><given-names>F.</given-names></name>; <name><surname>Radich</surname><given-names>J. P.</given-names></name>; <name><surname>Branford</surname><given-names>S.</given-names></name>; <name><surname>Hughes</surname><given-names>T. P.</given-names></name>; <name><surname>Baccarani</surname><given-names>M.</given-names></name>; <name><surname>Deininger</surname><given-names>M. W.</given-names></name>; <name><surname>Cervantes</surname><given-names>F.</given-names></name>; <name><surname>Fujihara</surname><given-names>S.</given-names></name>; <name><surname>Ortmann</surname><given-names>C. E.</given-names></name>; <name><surname>Menssen</surname><given-names>H. D.</given-names></name>; <name><surname>Kantarjian</surname><given-names>H.</given-names></name>; <name><surname>O’Brien</surname><given-names>S. G.</given-names></name>; <name><surname>Druker</surname><given-names>B. J.</given-names></name>; <article-title>Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid
Leukemia</article-title>. <source>N. Engl. J. Med.</source><year>2017</year>, <volume>376</volume> (<issue>10</issue>), <fpage>917</fpage>–<lpage>927</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1609324</pub-id>.<pub-id pub-id-type="pmid">28273028</pub-id></mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="journal" id="cit25"><name><surname>Parker</surname><given-names>J. S.</given-names></name>; <name><surname>Mullins</surname><given-names>M.</given-names></name>; <name><surname>Cheang</surname><given-names>M. C. U.</given-names></name>; <name><surname>Leung</surname><given-names>S.</given-names></name>; <name><surname>Voduc</surname><given-names>D.</given-names></name>; <name><surname>Vickery</surname><given-names>T.</given-names></name>; <name><surname>Davies</surname><given-names>S.</given-names></name>; <name><surname>Fauron</surname><given-names>C.</given-names></name>; <name><surname>He</surname><given-names>X.</given-names></name>; <name><surname>Hu</surname><given-names>Z.</given-names></name>; <name><surname>Quackenbush</surname><given-names>J. F.</given-names></name>; <name><surname>Stijleman</surname><given-names>I. J.</given-names></name>; <name><surname>Palazzo</surname><given-names>J.</given-names></name>; <name><surname>Marron</surname><given-names>J. S.</given-names></name>; <name><surname>Nobel</surname><given-names>A. B.</given-names></name>; <name><surname>Mardis</surname><given-names>E.</given-names></name>; <name><surname>Nielsen</surname><given-names>T. O.</given-names></name>; <name><surname>Ellis</surname><given-names>M. J.</given-names></name>; <name><surname>Perou</surname><given-names>C. M.</given-names></name>; <name><surname>Bernard</surname><given-names>P. S.</given-names></name><article-title>Supervised Risk Predictor of Breast Cancer Based on Intrinsic
Subtypes</article-title>. <source>J. Clin. Oncol.</source><year>2009</year>, <volume>27</volume> (<issue>8</issue>), <fpage>1160</fpage>–<lpage>1167</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2008.18.1370</pub-id>.<pub-id pub-id-type="pmid">19204204</pub-id></mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Perou</surname><given-names>C. M.</given-names></name>; <name><surname>Sørlie</surname><given-names>T.</given-names></name>; <name><surname>Eisen</surname><given-names>M. B.</given-names></name>; <name><surname>van de Rijn</surname><given-names>M.</given-names></name>; <name><surname>Jeffrey</surname><given-names>S. S.</given-names></name>; <name><surname>Rees</surname><given-names>C. A.</given-names></name>; <name><surname>Pollack</surname><given-names>J. R.</given-names></name>; <name><surname>Ross</surname><given-names>D. T.</given-names></name>; <name><surname>Johnsen</surname><given-names>H.</given-names></name>; <name><surname>Akslen</surname><given-names>L. A.</given-names></name>; <name><surname>Fluge</surname><given-names>O.</given-names></name>; <name><surname>Pergamenschikov</surname><given-names>A.</given-names></name>; <name><surname>Williams</surname><given-names>C.</given-names></name>; <name><surname>Zhu</surname><given-names>S. X.</given-names></name>; <name><surname>Lønning</surname><given-names>P. E.</given-names></name>; <name><surname>Børresen-Dale</surname><given-names>A. L.</given-names></name>; <name><surname>Brown</surname><given-names>P. O.</given-names></name>; <name><surname>Botstein</surname><given-names>D.</given-names></name><article-title>Molecular Portraits of Human Breast Tumours</article-title>. <source>Nature</source><year>2000</year>, <volume>406</volume> (<issue>6797</issue>), <fpage>747</fpage>–<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1038/35021093</pub-id>.<pub-id pub-id-type="pmid">10963602</pub-id></mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Lim</surname><given-names>R. C. C.</given-names></name>; <name><surname>Price</surname><given-names>J. T.</given-names></name>; <name><surname>Wilce</surname><given-names>J. A.</given-names></name><article-title>Context-Dependent Role of Grb7 in HER2+ve and Triple-Negative Breast Cancer
Cell Lines</article-title>. <source>Breast Cancer Res. Treat.</source><year>2014</year>, <volume>143</volume> (<issue>3</issue>), <fpage>593</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-014-2838-5</pub-id>.<pub-id pub-id-type="pmid">24464577</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Bivin</surname><given-names>W. W.</given-names></name>; <name><surname>Yergiyev</surname><given-names>O.</given-names></name>; <name><surname>Bunker</surname><given-names>M. L.</given-names></name>; <name><surname>Silverman</surname><given-names>J. F.</given-names></name>; <name><surname>Krishnamurti</surname><given-names>U.</given-names></name><article-title>GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast
Carcinoma</article-title>. <source>Appl. Immunohistochem. Mol. Morphol.</source><year>2017</year>, <volume>25</volume> (<issue>8</issue>), <fpage>553</fpage>–<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1097/PAI.0000000000000349</pub-id>.<pub-id pub-id-type="pmid">26945445</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
